Anixa Story

ANIX -- USA Stock

USD 4.30 0.15 3.37%

Macroaxis Story

Anixa Biosciences is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 14th of January 2021. The stock is in a buyout trend. Anixa Biosciences Sales per Share is fairly stable at the moment as compared to the past year. Anixa Biosciences reported Sales per Share of 0.0117 in 2020. Net Cash Flow or Change in Cash and Cash Equivalents is likely to rise to about 540.7 K in 2021, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (11.3 M) in 2021. While some baby boomers are getting worried about healthcare space, it is reasonable to break down Anixa Biosciences as an investment alternative. I will address a few possible reasons investors do not currently respect this stock.

Published over a week ago

View all stories for Anixa Biosciences | View All Stories

You think Anixa Biosciences (NASDAQ:ANIX) debt is an issue for investors?

This firm currently holds 68.76 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. On a scale of 0 to 100, Anixa Biosciences holds a performance score of 8. The firm shows a Beta (market volatility) of 0.3329, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Anixa's beta means in this case. As returns on the market increase, Anixa Biosciences returns are expected to increase less than the market. However, during the bear market, the loss on holding Anixa Biosciences will be expected to be smaller as well. Although it is vital to follow Anixa Biosciences historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Anixa Biosciences, which you can use to evaluate the performance of the firm. Please makes use of Anixa Biosciences sortino ratio, as well as the relationship between the semi variance and rate of daily change to make a quick decision on whether Anixa Biosciences price patterns will revert.

Anixa Biosciences financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Anixa Biosciences, including all of Anixa Biosciences's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Anixa Biosciences assets, the company is considered highly leveraged. Understanding the composition and structure of overall Anixa Biosciences debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding Anixa Total Debt

Anixa Biosciences liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Anixa Biosciences has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Anixa Biosciences balance sheet include debt obligations and money owed to different Anixa Biosciences vendors, workers, and loan providers. Below is the chart of Anixa main long-term debt accounts currently reported on its balance sheet.

You can use Anixa Biosciences financial leverage analysis tool to get a better grip on understanding its financial position

How important is Anixa Biosciences's Liquidity

Anixa Biosciences financial leverage refers to using borrowed capital as a funding source to finance Anixa Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Anixa Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Anixa Biosciences's total debt and its cash.

Acquisition by Michael Catelani of 100000 shares of Anixa Biosciences subject to Rule 16b-3

Legal trades by Anixa Biosciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Anixa insider trading alert for grant of employee stock option (right to buy) by Michael Catelani, COO & CFO, on 28th of December 2020. This event was filed by Anixa Biosciences Inc with SEC on 2020-12-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Anixa Biosciences Indicators

The current price rise of Anixa Biosciences could raise concerns from investors as the firm it trading at a share price of 3.70 on 305,849 in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 5.58. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Anixa Biosciences partners.

Asset Breakdown

	Total Assets	6.15 Million
	Current Assets	6.11 Million
	Assets Non Current	185,262
	Goodwill	773,586

Our perspective of the current Anixa Biosciences rise

Semi deviation is down to 4.78. It may suggest a possible volatility slide. As of the 7th of January, Anixa Biosciences shows the Mean Deviation of 3.69, risk adjusted performance of 0.1133, and Downside Deviation of 5.31. Anixa Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Anixa Biosciences, which can be compared to its rivals. Please confirm Anixa Biosciences semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if Anixa Biosciences is priced correctly, providing market reflects its regular price of 3.7 per share. Given that Anixa Biosciences has jensen alpha of 0.4601, we suggest you to validate Anixa Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.

Our Bottom Line On Anixa Biosciences

While few other entities within the diagnostics & research industry are still a little expensive, even after the recent corrections, Anixa Biosciences may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Anixa nor drop your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Anixa Biosciences.

About Contributor

Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Anixa Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC